TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ZNTL stock, giving a Buy rating on October 27.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren’s rating is based on Zentalis Pharmaceuticals’ promising clinical progress and strategic focus. The ongoing enrollment in the DENALI Part 2 study for CCNE1+ PROC, which is expected to yield significant topline data by the end of 2026, positions the company well for potential accelerated approval. This strategic focus on PROC, rather than further investment in USC, is seen as a prudent allocation of resources.
Furthermore, the clinical data from previous trials, including Phase Ia, MAMMOTH, and DENALI, have demonstrated a notable improvement over standard chemotherapy treatments. With an objective response rate of 31-35% and a median duration of response between 4.2-6.3 months, Zentalis’ azeno treatment shows a clear advantage, reinforcing the potential for successful outcomes in the ongoing trials. These factors collectively underpin the Buy rating given by Tyler Van Buren.
In another report released on October 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.